Clinical Trial

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Study acronym: MEGA-TACT-BC3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-15
Trial Details
NCT Number NCT07543536
Lead Sponsor Sun Yat-sen University
Conditions Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
Enrollment 132 participants
Start Date 2026-06-08
Primary Completion 2029-04-01 (estimated)
Study Completion 2031-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14